Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease

被引：15
作者：
Lee, Han Ah [1 ]
Kim, Hwi Young [1 ]
机构：
[1] Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul 07985, South Korea
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 11期
基金：
新加坡国家研究基金会;
关键词：
nonalcoholic steatohepatitis; diabetes; liraglutide; semaglutide; tirzepatide; HEPATIC STEATOSIS; GLP-1; ANALOG; VITAMIN-E; DUAL GIP; LIRAGLUTIDE; METFORMIN; OBESITY; TRIAL; STEATOHEPATITIS; ADIPONECTIN;
D O I：
10.3390/ijms24119324
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Nonalcoholic fatty liver disease (NAFLD) can lead to liver fibrosis and cirrhosis. Recently, glucagon-like peptide 1 receptor agonists (GLP-1RAs), a class of drugs used to treat type 2 diabetes and obesity, have shown therapeutic effects against NAFLD. In addition to reducing blood glucose levels and body weight, GLP-1RAs are effective in improving the clinical, biochemical, and histological markers of hepatic steatosis, inflammation, and fibrosis in patients with NAFLD. Additionally, GLP-1RAs have a good safety profile with minor side effects, such as nausea and vomiting. Overall, GLP-1RAs show promise as a potential treatment for NAFLD, and further studies are required to determine their long-term safety and efficacy.
引用
收藏
页数：17
相关论文
共 66 条
  • [1] The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials
    Aldawsari, Malikah
    Almadani, Fatima A.
    Almuhammadi, Nujud
    Algabsani, Sarah
    Alamro, Yara
    Aldhwayan, Madhawi
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 : 575 - 595
  • [2] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021
    不详
    [J]. DIABETES CARE, 2021, 44 : S111 - S124
  • [3] Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
    Armstrong, Matthew J.
    Hull, Diana
    Guo, Kathy
    Barton, Darren
    Hazlehurst, Jonathan M.
    Gathercole, Laura L.
    Nasiri, Maryam
    Yu, Jinglei
    Gough, Stephen C.
    Newsome, Philip N.
    Tomlinson, Jeremy W.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 (02) : 399 - 408
  • [4] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
    Armstrong, Matthew James
    Gaunt, Piers
    Aithal, Guruprasad P.
    Barton, Darren
    Hull, Diana
    Parker, Richard
    Hazlehurst, Jonathan M.
    Guo, Kathy
    Abouda, George
    Aldersley, Mark A.
    Stocken, Deborah
    Gough, Stephen C.
    Tomlinson, Jeremy W.
    Brown, Rachel M.
    Huebscher, Stefan G.
    Newsome, Philip N.
    [J]. LANCET, 2016, 387 (10019) : 679 - 690
  • [5] Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
    Ben-Shlomo, Shani
    Zvibel, Isabel
    Shnell, Mati
    Shlomai, Amir
    Chepurko, Elena
    Halpern, Zamir
    Barzilai, Nir
    Oren, Ran
    Fishman, Sigal
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 (06) : 1214 - 1223
  • [6] Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation
    Bizino, Maurice B.
    Jazet, Ingrid M.
    de Heer, Paul
    van Eyk, Huub J.
    Dekkers, Ilona A.
    Rensen, Patrick C. N.
    Paiman, Elisabeth H. M.
    Lamb, Hildebrandus J.
    Smit, Johannes W.
    [J]. DIABETOLOGIA, 2020, 63 (01) : 65 - 74
  • [7] Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis
    Borodavkin, Petr
    Sheridan, William
    Coelho, Claudia
    Ostarijas, Eduard
    Zair, Zoulikha M.
    Miras, Alexander D.
    McGowan, Barbara
    le Roux, Carel W.
    Vincent, Royce P.
    Dimitriadis, Georgios K.
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (02) : 337 - 342
  • [8] Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial
    Bouchi, Ryotaro
    Nakano, Yujiro
    Fukuda, Tatsuya
    Takeuchi, Takato
    Murakami, Masanori
    Minami, Isao
    Izumiyama, Hajime
    Hashimoto, Koshi
    Yoshimoto, Takanobu
    Ogawa, Yoshihiro
    [J]. ENDOCRINE JOURNAL, 2017, 64 (03) : 269 - 281
  • [9] A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
    Bugianesi, E
    Gentilcore, E
    Manini, R
    Natale, S
    Vanni, E
    Villanova, N
    David, E
    Rizzetto, M
    Marchesini, G
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (05) : 1082 - 1090
  • [10] 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (vol 43, pg 487, 2020)
    Buse, John B.
    Wexler, Deborah J.
    Tsapas, Apostolos
    Rossing, Peter
    Mingrone, Geltrude
    Mathieu, Chantal
    D'Alessio, David A.
    Davies, Melanie J.
    [J]. DIABETES CARE, 2020, 43 (07) : 1670 - 1670
1234567